Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy

S.P. Li, A. Makris, M.J. Beresford, N.J. Taylor, M.L.W. Ah-See, J.J. Stirling, J.A. d'Arcy, D.J. Collins, Robert Kozarski, A.R. Padhani

    Research output: Contribution to journalArticlepeer-review

    62 Citations (Scopus)


    Purpose : To investigate whether early changes in vascular parameters determined with dynamic contrast material–enhanced magnetic resonance (MR) imaging after two cycles of neoadjuvant chemotherapy (NAC) are predictive of disease-free and overall survival in primary breast cancer.
    Materials and Methods : Institutional ethics approval and informed consent were obtained. Patients with primary breast cancer (median age, 45 years; age range, 22–70 years) recruited from January 2001 to September 2008 underwent dynamic contrast-enhanced MR imaging before and after two cycles of NAC. Quantitative and semiquantitative kinetic parameters were calculated, including the volume transfer constant (Ktrans) and the initial area under the gadolinium concentration–time curve over 60 seconds (IAUGC60). Cut points optimized to the receiver operating characteristic curve were used to dichotomize MR imaging data for Kaplan-Meier survival analysis. MR imaging parameters and known prognostic indicators in primary breast cancer were correlated with disease-free and overall survival by using the Cox proportional hazards model for univariate and multivariate analyses.
    Results : MR imaging was performed before (n = 62) and after (n = 58) two cycles of NAC. The median follow-up time was 43.9 months for disease-free survival and 60.3 months for overall survival. There were 28 recurrences; 26 patients had distant metastases (two had additional local recurrence) and two had local recurrence only. There were 20 deaths, all of which were related to breast cancer. At univariate analysis, progesterone receptor status, the type of surgery performed, higher posttreatment Ktrans (P = .048), and larger posttreatment IAUGC60 (P = .035) were significant predictors of worse disease-free survival. At multivariate analysis, progesterone receptor status (P = .002) and mean transit time (P = .025) were significant predictors of disease-free survival. Univariate analysis showed that clinical tumor stage (P = .005), progesterone receptor status (P = .025), and type of surgery performed (P = .017) were significant predictors of overall survival. Higher posttreatment Ktrans (P = .043), larger IAUGC60 (P = .029), and larger tumor size at posttreatment MR imaging were predictive of worse overall survival (P = .018). Of these variables, Ktrans remained an independent indicator of overall survival (P = .038).
    Conclusion : Higher posttreatment tumor vascularization as depicted with dynamic contrast-enhanced MR imaging may be associated with higher recurrence and lower survival rates. Dynamic contrast-enhanced MR imaging parameters, in conjunction with traditional prognostic factors, have the potential to be prognostic biomarkers for disease-free and overall survival in primary breast cancer.
    Original languageEnglish
    Pages (from-to)68-78
    Number of pages11
    Issue number1
    Publication statusPublished - 2011


    • Nottingham prognostic index
    • DCE-MRI
    • clinical response
    • KI67 expression
    • therapy
    • carcinoma
    • sorafenib
    • kinetics


    Dive into the research topics of 'Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy'. Together they form a unique fingerprint.

    Cite this